1. Home
  2. LZM vs ALT Comparison

LZM vs ALT Comparison

Compare LZM & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LZM
  • ALT
  • Stock Information
  • Founded
  • LZM 2021
  • ALT 1997
  • Country
  • LZM Isle of Man
  • ALT United States
  • Employees
  • LZM N/A
  • ALT N/A
  • Industry
  • LZM Metal Mining
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • LZM Basic Materials
  • ALT Health Care
  • Exchange
  • LZM Nasdaq
  • ALT Nasdaq
  • Market Cap
  • LZM 371.9M
  • ALT 292.0M
  • IPO Year
  • LZM N/A
  • ALT N/A
  • Fundamental
  • Price
  • LZM $4.53
  • ALT $3.83
  • Analyst Decision
  • LZM Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • LZM 1
  • ALT 6
  • Target Price
  • LZM $14.00
  • ALT $17.40
  • AVG Volume (30 Days)
  • LZM 89.0K
  • ALT 3.0M
  • Earning Date
  • LZM 08-11-2025
  • ALT 08-12-2025
  • Dividend Yield
  • LZM N/A
  • ALT N/A
  • EPS Growth
  • LZM N/A
  • ALT N/A
  • EPS
  • LZM N/A
  • ALT N/A
  • Revenue
  • LZM $416,323.00
  • ALT $20,000.00
  • Revenue This Year
  • LZM $611.56
  • ALT N/A
  • Revenue Next Year
  • LZM $344.44
  • ALT $761,880.20
  • P/E Ratio
  • LZM N/A
  • ALT N/A
  • Revenue Growth
  • LZM N/A
  • ALT N/A
  • 52 Week Low
  • LZM $2.90
  • ALT $2.90
  • 52 Week High
  • LZM $7.29
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • LZM 46.66
  • ALT 51.79
  • Support Level
  • LZM $4.21
  • ALT $3.35
  • Resistance Level
  • LZM $4.74
  • ALT $3.66
  • Average True Range (ATR)
  • LZM 0.20
  • ALT 0.19
  • MACD
  • LZM -0.01
  • ALT 0.07
  • Stochastic Oscillator
  • LZM 25.00
  • ALT 86.18

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: